Sugi Predict

Sugi Predict / Targets / PTPN9

PTPN9

Tyrosine-protein phosphatase non-receptor type 9 · P43378 · PTPN9 on Sugi Atlas →

984 patent compounds predicted against PTPN9, 684 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15829171 SCHEMBL15829171 0.81 14/20
SCHEMBL18231231 SCHEMBL18231231 0.67 14/20
SCHEMBL22733587 SCHEMBL22733587 0.57 14/20
SCHEMBL15829170 SCHEMBL15829170 0.81 13/20
SCHEMBL15829174 SCHEMBL15829174 1.00 12/20
SCHEMBL13737097 SCHEMBL13737097 1.00 11/20
SCHEMBL15829183 SCHEMBL15829183 0.78 11/20
SCHEMBL15829184 SCHEMBL15829184 0.78 11/20
SCHEMBL15829167 SCHEMBL15829167 0.77 11/20
SCHEMBL13734913 SCHEMBL13734913 1.00 10/20
SCHEMBL13734961 SCHEMBL13734961 1.00 10/20
SCHEMBL15829160 SCHEMBL15829160 0.88 10/20
SCHEMBL15829159 SCHEMBL15829159 0.83 10/20
SCHEMBL18231232 SCHEMBL18231232 0.80 10/20
SCHEMBL15829186 SCHEMBL15829186 0.75 10/20
SCHEMBL15829166 SCHEMBL15829166 0.70 10/20
SCHEMBL15829172 SCHEMBL15829172 0.70 10/20
SCHEMBL15829180 SCHEMBL15829180 0.52 10/20
SCHEMBL15829181 SCHEMBL15829181 1.00 9/20
SCHEMBL15829168 SCHEMBL15829168 0.74 9/20

Clinical trials — most relevant to PTPN9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia PHASE2UNKNOWN
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer PHASE2RECRUITING
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors PHASE1RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms nanNOT_YET_RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Resistance to Immunotherapy in Gastric Cancer nanUNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Cardiovascular Effects of Empagliflozine nanUNKNOWN
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPN9 binder may also engage these)

ProteinNameSimilarity
Q641Z2 — 1.000 Q641Z2 →
O35239 — 1.000 O35239 →
P35234 — 0.987 P35234 →
B2GV87 — 0.986 B2GV87 →
P49446 — 0.985 P49446 →
P58875 — 0.985 P58875 →
PTPRE Receptor-type tyrosine-protein phosphatase epsilon 0.985 landscape →
P10686 — 0.984 P10686 →
PTPRA Receptor-type tyrosine-protein phosphatase alpha 0.984 landscape →
Q62077 — 0.984 Q62077 →
PLCG1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 0.983 landscape →
B4NBB0 — 0.983 B4NBB0 →
B0XDC4 — 0.983 B0XDC4 →
PTPN6 Tyrosine-protein phosphatase non-receptor type 6 0.983 landscape →
P29351 — 0.983 P29351 →
Q8R0F9 — 0.983 Q8R0F9 →
Q80YE7 — 0.983 Q80YE7 →
DAPK1 Death-associated protein kinase 1 0.983 landscape →
P41499 — 0.982 P41499 →
Q5I142 — 0.982 Q5I142 →
P35235 — 0.982 P35235 →
Q9JJH5 — 0.982 Q9JJH5 →
Q9H1H9 — 0.982 Q9H1H9 →
O76054 — 0.981 O76054 →
P18052 — 0.981 P18052 →
Q6DEH3 — 0.981 Q6DEH3 →
P92006 — 0.981 P92006 →
B5MCN3 — 0.981 B5MCN3 →
P70265 — 0.981 P70265 →
Q16KN5 — 0.981 Q16KN5 →